CClinicalTrials.gg
CompletedNCT02655978Updated Nov 12, 2020

Rostral Dorsal Cingulum Bundle Connectivity in Patients With Bipolar Disorder

An observational study in Bipolar Disorder, sponsored by University Hospitals Cleveland Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-12.

Sponsored by University Hospitals Cleveland Medical Center · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
45
Ages
18 Years and older
Sex
All
01

Study summary

The overall goal of this study is to employ diffusion-weighted imaging (DWI) and tractography to investigate differences in connectivity in the rostral dorsal cingulum bundle (CB) in patients with bipolar disorder type I (BDI) or bipolar type II (BDII) compared to matched controls, and to utilize this information to determine if high-frequency deep brain stimulation (DBS) of the rostral dorsal CB has realistic potential as a therapy for producing mood stabilization in patients with BDI or BDII.

02

Conditions studied

  • Bipolar Disorder

Browse trials for

03

In context

Bipolar Disorder

1,601 studies on the registry are indexed under Bipolar Disorder; 255 are open to participants now.

This study's enrollment of 45 is below the median of 159 across 330 observational studies indexed under Bipolar Disorder.

Browse Bipolar Disorder studies →

Lead sponsor

University Hospitals Cleveland Medical Center is the lead sponsor of 283 studies on the registry; 42 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 29 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants from all three groups will be made up of those who respond to IRB approved advertisements or are referred by a provider within the UHCMC Department of Psychiatry or other provider referral.

Eligibility criteria

  1. Inclusion and Exclusion Criteria for Group 1: Healthy Volunteers

    a. Inclusion Criteria for Group 1:

    i. Male or female, age 18 or older

    ii. In the opinion of the investigator, capable of understanding and complying with protocol requirements

    iii. In the opinion of the investigator, has the competency to understand and sign the informed consent

    iv. Physically healthy

    v. Without any current and/or lifetime psychiatric disorder assessed with a Structured Clinical Interview for psychiatric Disorders, including the Mini International Neuropsychiatric Interview (MINI)

    b. Exclusion Criteria for Group 1:

    i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis)

    ii. Progressive neurological disease such as neurodegenerative disease

    iii. Preexisting implanted electrical device (such as pacemaker or cardiac defibrillator)

    iv. Any psychiatric disorder including any severe personality disorder

    v. Currently pregnant or planning to become pregnant

    vi. Any other contraindications to the brain imaging procedures.

    vii. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription

    viii. Currently taking any steroids, stimulants, or opioid pain killers.

    ix. Currently experiencing nicotine dependence or any smoking of cigarettes or use of other nicotine containing products within a week before the imaging visit.

  2. Inclusion and Exclusion Criteria for Group 2: Medically Treatment-Responsive Bipolar Disorder

    a. Inclusion Criteria for Group 2:

    i. Male or female, age 18 or older

    ii. In the opinion of the investigator, capable of understanding and complying with protocol requirements

    iii. In the opinion of the investigator, has the competency to understand and sign the informed consent

    iv. Meets diagnostic criteria for BDI or BDII according to the DSM-V criteria, as confirmed by a systematic clinical interview and the administration of the MINI

    v. A recent episode of depression, currently in remission with evidence-based treatments for bipolar disorder

    vi. Montgomery-Asberg Depression Rating Scale (MADRS) total score ≤ 10

    vii. Young Mania Rating Scale (YMRS, Young et al 1988) total score ≤ 8

    viii. Global Clinical Impression-Severity for Bipolar Disorder (CGI-S-BD) ≤ 2

    ix. Subject is compliant with taking medication per the investigator's discretion

    b. Exclusion Criteria for Group 2:

    i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis)

    ii. Progressive neurological disease such as neurodegenerative disease

    iii. Preexisting implanted electrical device (such as pacemaker or cardiac defibrillator)

    iv. Contribution of any co-occurring psychiatric comorbidity that is disproportionate to the contribution of BDI or BDII, such as severe obsessive-compulsive disorder (OCD) or post-traumatic stress disorder (PTSD)

    v. Meets criteria for antisocial personality disorder

    vi. Meets criteria for having borderline personality disorder

    vii. There will be no exclusions based on prescribed CNS-active medications

    viii. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription

    ix. Meets DSM-V criteria for any alcohol and/or drug use disorder within the last 6 months, excluding the use of caffeine and/or nicotine

    x. Currently pregnant or planning to become pregnant

    xi. Any other contraindications to the brain imaging procedures.

  3. Inclusion and Exclusion Criteria for Group 3: Treatment-Refractory Bipolar Disorder

    a. Inclusion Criteria for Group 3:

    i. Male or female, age 18 or older

    ii. In the opinion of the investigator, capable of understanding and complying with protocol requirements

    iii. In the opinion of the investigator, has the competency to understand and sign the informed consent

    iv. Meets diagnostic criteria for BDI or BDII, currently depressed, at least moderately severe with or without psychotic features, according to the DSM-V criteria, as confirmed by a systematic clinical interview and the administration of the Structured Clinical Interview for Psychiatric Disorders, including the Mini International Neuropsychiatric Interview (MINI)

    v. Current episode lasting at least 6 months and not responding to 2 adequate evidence-based treatments for BDI or BDII assessed with the assistance of Modified Antidepressant Treatment History Form (MATHF) and verified through medical records if possible

    vi. If a subject has refused treatment with a particular FDA-approved mood stabilizer due to reasons of unacceptable side effects (such as weight gain, etc.), their wishes will be respected

    vii. Depression severity should be measured with Montgomery-Asberg Depression Rating Scale (MADRS). A MADRS total score ≥ 20 is required at Screening Visit/Baseline Evaluation.

    viii. Has experienced marked impairment as documented by a score consistent with severe impairment (7 or more on at least one of the three subscales of the Sheehan Disability Scale (SDS), which includes an assessment of work-life, family-life, and social life (no/mild impairment 0-3, moderate impairment 4-6, severe impairment 7-10)

    ix. Bipolar disorder and current depressive episode as the primary source of the patient's disability, according to both the subject and the psychiatrist

    b. Exclusion Criteria for Group 3:

    i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis)

    ii. Progressive neurological disease such as neurodegenerative disease

    iii. Preexisting implanted electrical device (such as pacemaker or cardiac defibrillator)

    iv. Contribution of any co-occurring psychiatric comorbidity that disproportionate to the contribution of BDI or BDII, such as severe obsessive-compulsive disorder (OCD) or post-traumatic stress disorder (PTSD)

    v. Meets criteria for antisocial personality disorder

    vi. Meets criteria for having borderline personality disorder

    vii. There will be no exclusions based on prescribed CNS-active medications

    viii. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription

    ix. Meets DSM-V criteria for any alcohol and/or drug use disorder within the last 6 months, excluding the use of caffeine and/or nicotine

    x. Active suicidal ideation with a plan or intent, a suicide attempt within past 6 months or more than 2 suicide attempts within the past 2 years

    xi. Currently pregnant or planning to become pregnant

    xii. Any other contraindications to the brain imaging procedures.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
45 participants (actual)
Patient registry
No

Groups and cohorts

  • Healthy Volunteers

    These participants will not have any psychiatric disorder as assessed by a structured clinical interview for psychiatric disorders.

    Other: Magnetic Resonance Imaging

  • Medically Treatment-Responsive BD

    This group will be composed of participants who have BDI or BDII and have most recently been depressed but are currently in remission with evidence-based treatments for bipolar disorder

    Other: Magnetic Resonance Imaging

  • Treatment-Refractory BD

    This group will be composed of participants who have BDI or BDII, are currently depressed with their current episode lasting at least 12 months and not responding to 4 adequate evidence-based treatments for BDI or BDII and who have failed, been intolerant to, or were unwilling to try electroconvulsive therapy (ECT).

    Other: Magnetic Resonance Imaging

Interventions

  • OtherMagnetic Resonance Imaging
06

What researchers measure

Primary outcomes

  1. Differences in connectivity in the rostral dorsal CB in patients with BDI or or BDII compared to matched controls

    The imaging visit will consist of an MRI with diffusion-weighted imaging (DWI) sequences

    Time frame: Day 1

07

Study locations

1 site
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02655978
Lead sponsor
University Hospitals Cleveland Medical Center
Collaborators
National Institutes of Health (NIH)
Responsible party
Jennifer Sweet, MD (Neurosurgeon, University Hospitals Cleveland Medical Center) — Principal investigator
First posted
Jan 14, 2016
Start date
Jan 2016
Primary completion
Oct 2019
Completion
Oct 2019
Last update
Nov 12, 2020

Study contacts

Jennifer A Sweet, MD
principal investigator · University Hospitals Cleveland Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion